Above all, inhibition of other HDAC subtypes would decrease the efficacy in CTCL, which inspired us targeting class I HDACs might increase the application of HDACI in TCL therapies. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.